Lan Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lan Xiao has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Lei Sun
Department of Obstetrics & Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publicationsCan-Can Duan
Department of Obstetrics & Gynecology, the First Affiliated Hospital, Anhui Medical University, Hefei, China
2 shared publicationsCheng Chen
Department of Obstetrics & Gynecology, the First Affiliated Hospital, Anhui Medical University, Hefei, China
2 shared publicationsZe-Lian Li
Department of Obstetrics & Gynecology, the First Affiliated Hospital, Anhui Medical University, Hefei, P. R. China
2 shared publications- Bairong Xia
Department of Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
1 shared publication - Bensheng Qiu
Medical Imaging Center, Department of Electronic Engineering and Information Science, University of Science and Technology of China, Hefei, China
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15  (39) , e71733
NeutrophilâMediated Delivery of MRIâTraceable Nanocarriers Ameliorates Acute Kidney Injury and Associated Cognitive Deficits and AnxietyâLike Behaviors
Acute kidney injury (AKI) frequently progresses to chronic kidney disease (CKD) and is increasingly linked to significant remote neuropsychiatric sequelae. However, current therapeutic strategies usually lack renal targeting and, critically, neglect to address these systemic comorbidities, particularly the associated cognitive deficits and anxietyâlike behaviors. In this study, we developed a biomimetic platform consisting of neutrophils loaded with superparamagnetic iron oxide nanoparticles encapsulating celastrol (termed NSPIOC), as an MRIâvisible theranostic system for targeted renal therapy and simultaneous mitigation of associated neuropsychiatric impairments. Systemically administered NSPIOC leverage innate neutrophil chemotaxis to home toward renal inflammatory gradients. Upon infiltration, inflammationâtriggered NETosis releases the cargo into vulnerable proximal tubules, while T 2 âweighted MRI enables realâtime monitoring of neutrophil recruitment. Our results demonstrate that NSPIOC effectively restore renal function and inhibits the AKIâtoâCKD transition. Importantly, our findings provide new evidence that renalâtargeted intervention can alleviate AKIâinduced cognitive deficits and anxietyâlike behaviors. Mechanistically, restoring renal homeostasis prevents the pathological hyperactivation of glutamatergic neurons in the medial prefrontal cortex (mPFC). This biomimetic platform offers a holistic strategy for managing AKI by simultaneously addressing primary renal injury and remote neurological dysfunction, presenting a promising approach to systemic inflammatory complications.
- 21 September 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15  (39) , e71733
Open AccessNeutrophilâMediated Delivery of MRIâTraceable Nanocarriers Ameliorates Acute Kidney Injury and Associated Cognitive Deficits and AnxietyâLike Behaviors
Acute kidney injury (AKI) frequently progresses to chronic kidney disease (CKD) and is increasingly linked to significant remote neuropsychiatric sequelae. However, current therapeutic strategies usually lack renal targeting and, critically, neglect to address these systemic comorbidities, particularly the associated cognitive deficits and anxietyâlike behaviors. In this study, we developed a biomimetic platform consisting of neutrophils loaded with superparamagnetic iron oxide nanoparticles encapsulating celastrol (termed NSPIOC), as an MRIâvisible theranostic system for targeted renal therapy and simultaneous mitigation of associated neuropsychiatric impairments. Systemically administered NSPIOC leverage innate neutrophil chemotaxis to home toward renal inflammatory gradients. Upon infiltration, inflammationâtriggered NETosis releases the cargo into vulnerable proximal tubules, while T 2 âweighted MRI enables realâtime monitoring of neutrophil recruitment. Our results demonstrate that NSPIOC effectively restore renal function and inhibits the AKIâtoâCKD transition. Importantly, our findings provide new evidence that renalâtargeted intervention can alleviate AKIâinduced cognitive deficits and anxietyâlike behaviors. Mechanistically, restoring renal homeostasis prevents the pathological hyperactivation of glutamatergic neurons in the medial prefrontal cortex (mPFC). This biomimetic platform offers a holistic strategy for managing AKI by simultaneously addressing primary renal injury and remote neurological dysfunction, presenting a promising approach to systemic inflammatory complications.
- Open Access
- 15 October 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18  (1) , 1-9
Post-translational modifications in ovarian cancer: implications for immunotherapy: a mini-review
Ovarian cancer (OC) is the most lethal gynecologic malignancies worldwide, is characterized by poor prognosis and limited treatment options. While immunotherapy has shown promise in treating gynecologic cancers, particularly OC, its efficacy against OC remains suboptimal due to the distinct immune evasion mechanisms within the OC tumor microenvironment (TME). Post-translational modifications (PTMs), which involve enzyme-catalyzed attachment of functional groups to proteins, inducing structural and functional alterations, are emerging as critical regulators in tumor immunotherapy. In this review, we comprehensively summarize various PTMs that modulate the immune response in OC, primarily including ubiquitination, phosphorylation, glycosylation, and acetylation. We specifically focus on how these PTMs modulate key immune checkpoint molecules and immune evasion. Elucidating the roles of PTMs in the OC immune response could provide novel strategies for enhancing the efficacy of immunotherapy.
- 15 October 2025
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 18  (1) , 1-9
Open AccessPost-translational modifications in ovarian cancer: implications for immunotherapy: a mini-review
Ovarian cancer (OC) is the most lethal gynecologic malignancies worldwide, is characterized by poor prognosis and limited treatment options. While immunotherapy has shown promise in treating gynecologic cancers, particularly OC, its efficacy against OC remains suboptimal due to the distinct immune evasion mechanisms within the OC tumor microenvironment (TME). Post-translational modifications (PTMs), which involve enzyme-catalyzed attachment of functional groups to proteins, inducing structural and functional alterations, are emerging as critical regulators in tumor immunotherapy. In this review, we comprehensively summarize various PTMs that modulate the immune response in OC, primarily including ubiquitination, phosphorylation, glycosylation, and acetylation. We specifically focus on how these PTMs modulate key immune checkpoint molecules and immune evasion. Elucidating the roles of PTMs in the OC immune response could provide novel strategies for enhancing the efficacy of immunotherapy.
- 12 April 2024
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- Vol. 89  (5) , 363-375
Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis
Introduction: DNA methylation plays an important role in the carcinogenesis, progression, and prognosis of various human cancers. RASSF1A, BRCA1, APC, and p16 are the frequently methylated genes among patients with ovarian cancer. Therefore, our study aimed to better determine the prognostic and cancer characteristics effects of RASSF1A, BRCA1, APC, and p16 promoter methylation in ovarian cancer patients. Methods: Databases such as PubMed, Web of Science, EMBASE, CNKI, and WanFang were searched for published studies up to March 4, 2024. The outcomes are shown as OR and HR with their 95% CIs. Then, the random or fixed-effect model was performed to evaluate the effect sizes. Results: Finally, 27 articles were included in this meta-analysis. No significant relationships were observed between RASSF1A, BRCA1, and APC promoter methylation and the clinical prognostic (including overall survival and progression-free survival) and cancer characteristics (including ascites, lymph node metastasis, and pelvic peritoneal metastasis) in ovarian cancer. p16 promoter methylation was significantly related to poor progression-free survival (PFS) (HR = 1.52, 95% CI = 1.14â2.04) and overall survival (OS) (HR = 1.39, 95% CI = 1.06, to 1.83) in univariate and poor PFS in multivariate Cox regression models (HR = 1.42, 95% CI = 1.05â1.92). Besides, our results indicated that the clinical stage was associated with inferior OS while there was no significant association between tumor grade and OS. Conclusion: RASSF1A, BRCA1, and APC promoter methylation were not significantly associated with clinical prognostic and cancer characteristics. p16 may be a useful biomarker for predicting PFS in ovarian cancer. Furthermore, the clinical stage was significantly associated with OS. In further research, more prospective and multicenter validation studies remain needed.
- 12 April 2024
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- Vol. 89  (5) , 363-375
Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis
Introduction: DNA methylation plays an important role in the carcinogenesis, progression, and prognosis of various human cancers. RASSF1A, BRCA1, APC, and p16 are the frequently methylated genes among patients with ovarian cancer. Therefore, our study aimed to better determine the prognostic and cancer characteristics effects of RASSF1A, BRCA1, APC, and p16 promoter methylation in ovarian cancer patients. Methods: Databases such as PubMed, Web of Science, EMBASE, CNKI, and WanFang were searched for published studies up to March 4, 2024. The outcomes are shown as OR and HR with their 95% CIs. Then, the random or fixed-effect model was performed to evaluate the effect sizes. Results: Finally, 27 articles were included in this meta-analysis. No significant relationships were observed between RASSF1A, BRCA1, and APC promoter methylation and the clinical prognostic (including overall survival and progression-free survival) and cancer characteristics (including ascites, lymph node metastasis, and pelvic peritoneal metastasis) in ovarian cancer. p16 promoter methylation was significantly related to poor progression-free survival (PFS) (HR = 1.52, 95% CI = 1.14â2.04) and overall survival (OS) (HR = 1.39, 95% CI = 1.06, to 1.83) in univariate and poor PFS in multivariate Cox regression models (HR = 1.42, 95% CI = 1.05â1.92). Besides, our results indicated that the clinical stage was associated with inferior OS while there was no significant association between tumor grade and OS. Conclusion: RASSF1A, BRCA1, and APC promoter methylation were not significantly associated with clinical prognostic and cancer characteristics. p16 may be a useful biomarker for predicting PFS in ovarian cancer. Furthermore, the clinical stage was significantly associated with OS. In further research, more prospective and multicenter validation studies remain needed.
- Open Access
- 8 September 2023
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 16  (1) , 1-16
The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells
Background: Cancer cells may develop resistance to cisplatin by various mechanisms. Yet, the exact mechanism of cisplatin in ovarian cancer remains unclear. Recent studies have shown that 3â-phospoadenosine 5â-phosphosulfate synthase 1 (PAPSS1) inhibition combined with low-dose cisplatin increases DNA damage. The aim of this study was to determine the value of targeting PAPSS1 as a cisplatin modulator in epithelial ovarian cancer (EOC). Results: Increased expression of PAPSS1 was observed in both EOC cells and tissues. Also, its higher nuclear expression was distinctly associated with FIGO (The International Federation of Gynecology and Obstetrics) stage, histological subtype, metastasis, and recurrence. Down-regulation of the PAPSS1 gene increased the cisplatin sensitivity of EOC in vitro and in vivo. Expression of PAPSS1 was negatively correlated with estrogen receptor Îħ (ERÎħ) in EOC. Also, low nuclear PAPSS1 and high nuclear ERÎħ expression in EOC were associated with longer overall survival and progression-free survival in all ovarian cancer and ovarian cancer patients who received platinum-based chemotherapy. PAPSS1 silencing increased the activity of ERÎħ-signaling in EOC cells, thus sensitizing tumors to cisplatin. Conclusions: These findings characterize a novel interplay between PAPSS1-mediated sulfation and ERÎħ-signaling in EOC cisplatin resistance. PAPSS1 may be exploited as a cisplatin-sensitizing therapeutic target.
- 8 September 2023
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 16  (1) , 1-16
Open AccessThe PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells
Background: Cancer cells may develop resistance to cisplatin by various mechanisms. Yet, the exact mechanism of cisplatin in ovarian cancer remains unclear. Recent studies have shown that 3â-phospoadenosine 5â-phosphosulfate synthase 1 (PAPSS1) inhibition combined with low-dose cisplatin increases DNA damage. The aim of this study was to determine the value of targeting PAPSS1 as a cisplatin modulator in epithelial ovarian cancer (EOC). Results: Increased expression of PAPSS1 was observed in both EOC cells and tissues. Also, its higher nuclear expression was distinctly associated with FIGO (The International Federation of Gynecology and Obstetrics) stage, histological subtype, metastasis, and recurrence. Down-regulation of the PAPSS1 gene increased the cisplatin sensitivity of EOC in vitro and in vivo. Expression of PAPSS1 was negatively correlated with estrogen receptor Îħ (ERÎħ) in EOC. Also, low nuclear PAPSS1 and high nuclear ERÎħ expression in EOC were associated with longer overall survival and progression-free survival in all ovarian cancer and ovarian cancer patients who received platinum-based chemotherapy. PAPSS1 silencing increased the activity of ERÎħ-signaling in EOC cells, thus sensitizing tumors to cisplatin. Conclusions: These findings characterize a novel interplay between PAPSS1-mediated sulfation and ERÎħ-signaling in EOC cisplatin resistance. PAPSS1 may be exploited as a cisplatin-sensitizing therapeutic target.
- Open Access
- 31 May 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23  (1) , 1-14
Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center
Background: The potential treatment effects of heat shock protein 90 (Hsp90) inhibitors in ovarian cancer (OC) are controversial. This research aims to investigate the relationship between the level of Hsp90 in peripheral blood and the prognosis of OC patients, as well as the clinicopathological indicators. Materials and methods: We retrospectively collected the clinicopathological indicators of OC patients who were admitted to the Department of Obstetrics and Gynecology of the First Affiliated Hospital of Anhui Medical University from 2017 to 2022. Hsp90 level in patient blood was detected by enzyme-linked immunosorbent assay, and the correlation between Hsp90 level and OC prognosis was systematically investigated. KaplanâMeier method was used to draw the survival curve, and the average survival time and survival rate were calculated. The log-rank test and Cox model were used for univariate survival analysis, and the Cox proportional hazards model was applied for multivariate survival analysis. Based on the TCGA dataset of OC obtained by cBioPortal, Pearsonâs correlation coefficients between Hsp90 level values and other mRNA expression values were calculated to further conduct bioinformatics analysis. GSEA and GSVA analysis were also conducted for gene functional enrichment. The expression of Hsp90 in OC tissues were evaluated and compared by Immunohistochemical staining. Results: According to the established screening criteria, 106 patients were selected. The enzyme-linked immunosorbent assay results showed that 50.94% OC patients with abnormal Hsp90 level. According to the outcome of KaplanâMeier curves, the results revealed that the abnormal level of Hsp90 was suggested to poor prognosis (P = 0.001) of OC patients. Furthermore, the result of multivariate Cox proportional hazards regression model analysis also predicted that abnormal Hsp90 level (HR = 2.838, 95%CI = 1.139â7.069, P = 0.025) was linked to poor prognosis, which could be an independent prognostic factor for the prognosis of OC patients. Moreover, top 100 genes screened by Pearsonâs value associated with Hsp90, indicating that Hsp90 participated in the regulation of ATF5 target genes, PRAGC1A target genes and BANP target genes and also enriched in the metabolic processes of cell response to DNA damage stimulus, response to heat and protein folding. Conclusion: Hsp90 level is positively associated with OC mortality and is a potential prognostic indicator of OC.
- 31 May 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23  (1) , 1-14
Open AccessHsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center
Background: The potential treatment effects of heat shock protein 90 (Hsp90) inhibitors in ovarian cancer (OC) are controversial. This research aims to investigate the relationship between the level of Hsp90 in peripheral blood and the prognosis of OC patients, as well as the clinicopathological indicators. Materials and methods: We retrospectively collected the clinicopathological indicators of OC patients who were admitted to the Department of Obstetrics and Gynecology of the First Affiliated Hospital of Anhui Medical University from 2017 to 2022. Hsp90 level in patient blood was detected by enzyme-linked immunosorbent assay, and the correlation between Hsp90 level and OC prognosis was systematically investigated. KaplanâMeier method was used to draw the survival curve, and the average survival time and survival rate were calculated. The log-rank test and Cox model were used for univariate survival analysis, and the Cox proportional hazards model was applied for multivariate survival analysis. Based on the TCGA dataset of OC obtained by cBioPortal, Pearsonâs correlation coefficients between Hsp90 level values and other mRNA expression values were calculated to further conduct bioinformatics analysis. GSEA and GSVA analysis were also conducted for gene functional enrichment. The expression of Hsp90 in OC tissues were evaluated and compared by Immunohistochemical staining. Results: According to the established screening criteria, 106 patients were selected. The enzyme-linked immunosorbent assay results showed that 50.94% OC patients with abnormal Hsp90 level. According to the outcome of KaplanâMeier curves, the results revealed that the abnormal level of Hsp90 was suggested to poor prognosis (P = 0.001) of OC patients. Furthermore, the result of multivariate Cox proportional hazards regression model analysis also predicted that abnormal Hsp90 level (HR = 2.838, 95%CI = 1.139â7.069, P = 0.025) was linked to poor prognosis, which could be an independent prognostic factor for the prognosis of OC patients. Moreover, top 100 genes screened by Pearsonâs value associated with Hsp90, indicating that Hsp90 participated in the regulation of ATF5 target genes, PRAGC1A target genes and BANP target genes and also enriched in the metabolic processes of cell response to DNA damage stimulus, response to heat and protein folding. Conclusion: Hsp90 level is positively associated with OC mortality and is a potential prognostic indicator of OC.
- Open Access
- 17 April 2022
- Published by Wiley in Cancer Medicine
- Vol. 11  (20) , 3761-3770
Better or worse? The prognostic role of the mesenchymal subtype in patients with highâgrade serous ovarian carcinoma: A systematic review and metaâanalysis
Background: Tumor characteristics can be prognostically relevant in patients with highâgrade serous ovarian carcinoma (HGSOC). This study aimed to determine whether different subtypes of HGSOC, especially the mesenchymal subtype, are associated with overall survival (OS) or progressionâfree survival (PFS) in patients with HGSOC.Methods: PubMed, Embase, and the Cochrane Library were searched for studies published up to September 2020. The eligibility criteria were (1) population: patients with HGSOG with molecular subtyping of their tumor, (2) exposure: mesenchymal subtype, (3) nonâexposure: differentiated, immunoreactive, proliferative, and other nonâmesenchymal subtypes, (4) outcome: survival, with hazard ratios (HRs), and (5) English language.Results: The mesenchymal subtype showed no statistically significant difference in OS compared with the immunoreactive subtype (HR = 1.47, 95% CI: 0.78â2.78, p = 0.238; I2 = 81.2%, pheterogeneity = 0.005) or all nonâmesenchymal subtypes (HR = 1.65, 95% CI: 0.97â2.80, p = 0.063; I2 = 79.4%, pheterogeneity = 0.008). The mesenchymal subtype showed no statistically significant difference in PFS compared with the immunoreactive subtype (HR = 1.19, 95% CI: 0.71â2.00, p = 0.514; I2 = 71.6%, pheterogeneity = 0.030) but a significant differences was observed when using all nonâmesenchymal subtypes as reference (HR = 1.51, 95% CI: 1.00â2.28, p = 0.049). The results were robust according to the sensitivity analyses.Conclusions: There are no statistically significant differences in OS between the mesenchymal subtype of HGSOC and other subtypes of HGSOC. Because of statistical power, this metaâanalysis cannot conclude about nonâinferiority, and the relationship between the molecular subtypes and HGSOC prognosis remains controversial. Based on one study, the mesenchymal subtype could have a poorer PFS than the nonâmesenchymal subtypes of HGSOC, but this conclusion requires further evidence.
- 17 April 2022
- Published by Wiley in Cancer Medicine
- Vol. 11  (20) , 3761-3770
Open AccessBetter or worse? The prognostic role of the mesenchymal subtype in patients with highâgrade serous ovarian carcinoma: A systematic review and metaâanalysis
Background: Tumor characteristics can be prognostically relevant in patients with highâgrade serous ovarian carcinoma (HGSOC). This study aimed to determine whether different subtypes of HGSOC, especially the mesenchymal subtype, are associated with overall survival (OS) or progressionâfree survival (PFS) in patients with HGSOC.Methods: PubMed, Embase, and the Cochrane Library were searched for studies published up to September 2020. The eligibility criteria were (1) population: patients with HGSOG with molecular subtyping of their tumor, (2) exposure: mesenchymal subtype, (3) nonâexposure: differentiated, immunoreactive, proliferative, and other nonâmesenchymal subtypes, (4) outcome: survival, with hazard ratios (HRs), and (5) English language.Results: The mesenchymal subtype showed no statistically significant difference in OS compared with the immunoreactive subtype (HR = 1.47, 95% CI: 0.78â2.78, p = 0.238; I2 = 81.2%, pheterogeneity = 0.005) or all nonâmesenchymal subtypes (HR = 1.65, 95% CI: 0.97â2.80, p = 0.063; I2 = 79.4%, pheterogeneity = 0.008). The mesenchymal subtype showed no statistically significant difference in PFS compared with the immunoreactive subtype (HR = 1.19, 95% CI: 0.71â2.00, p = 0.514; I2 = 71.6%, pheterogeneity = 0.030) but a significant differences was observed when using all nonâmesenchymal subtypes as reference (HR = 1.51, 95% CI: 1.00â2.28, p = 0.049). The results were robust according to the sensitivity analyses.Conclusions: There are no statistically significant differences in OS between the mesenchymal subtype of HGSOC and other subtypes of HGSOC. Because of statistical power, this metaâanalysis cannot conclude about nonâinferiority, and the relationship between the molecular subtypes and HGSOC prognosis remains controversial. Based on one study, the mesenchymal subtype could have a poorer PFS than the nonâmesenchymal subtypes of HGSOC, but this conclusion requires further evidence.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32  (5)
Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway
Xiao L, et al. J Gynecol Oncol. 2021 Jun;32(5):e77. https://doi.org/10.3802/jgo.2021.32.e77
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32  (5)
Open AccessDownregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway
Xiao L, et al. J Gynecol Oncol. 2021 Jun;32(5):e77. https://doi.org/10.3802/jgo.2021.32.e77
- Open Access
- 12 November 2019
- Published by Springer Nature in BMC Molecular and Cell Biology
- Vol. 20  (1) , 1-14
Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer
Background: Several reports indicated that the expression of Yes-associated protein (YAP) was associated with multi-drug resistance. Acidic microenvironment increased by the overexpression of vacuolar-ATPase (V-ATPase) was also observed in tumor growth and drug resistance. We hypothesize that proton pump inhibitors (PPIs), currently used in the anti-acid treatment of peptic disease, could inhibit the acidification of the tumor microenvironment and increase the sensitivity of tumor cells to cytotoxic agents. Thus, our objective is to explore the reversal of drug resistance by the inhibition of YAP through specific PPIs in the epithelial ovarian carcinoma (EOC) cells. . Results: We found that V-ATPase D1 was a positive regulator of YAP. Sub-lethal doses of the proton pump inhibitor esomeprazole (EMSO) in combination with paclitaxel (PTX) increased the PTX sensitivity in PTX-resistant EOC cells, as compared to PTX single treatments by inhibiting YAP and reserving pH gradient created by the V-ATPase D1. Moreover, sub-lethal doses of EMSO combined with PTX decreased autophagy and improved caspases independent apoptosis of PTX-resistant EOC cells. Conclusions: These results suggested that sub-lethal doses of esomeprazole reverse YAP-mediated PTX resistance through the inhibiting of both YAP expression and acidic tumor microenvironment created by the V-ATPase D1. Therefore, we think the use of PPIs represents a promising strategy to improve the effectiveness of anti-EOC.
- 12 November 2019
- Published by Springer Nature in BMC Molecular and Cell Biology
- Vol. 20  (1) , 1-14
Open AccessProton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer
Background: Several reports indicated that the expression of Yes-associated protein (YAP) was associated with multi-drug resistance. Acidic microenvironment increased by the overexpression of vacuolar-ATPase (V-ATPase) was also observed in tumor growth and drug resistance. We hypothesize that proton pump inhibitors (PPIs), currently used in the anti-acid treatment of peptic disease, could inhibit the acidification of the tumor microenvironment and increase the sensitivity of tumor cells to cytotoxic agents. Thus, our objective is to explore the reversal of drug resistance by the inhibition of YAP through specific PPIs in the epithelial ovarian carcinoma (EOC) cells. . Results: We found that V-ATPase D1 was a positive regulator of YAP. Sub-lethal doses of the proton pump inhibitor esomeprazole (EMSO) in combination with paclitaxel (PTX) increased the PTX sensitivity in PTX-resistant EOC cells, as compared to PTX single treatments by inhibiting YAP and reserving pH gradient created by the V-ATPase D1. Moreover, sub-lethal doses of EMSO combined with PTX decreased autophagy and improved caspases independent apoptosis of PTX-resistant EOC cells. Conclusions: These results suggested that sub-lethal doses of esomeprazole reverse YAP-mediated PTX resistance through the inhibiting of both YAP expression and acidic tumor microenvironment created by the V-ATPase D1. Therefore, we think the use of PPIs represents a promising strategy to improve the effectiveness of anti-EOC.
- Open Access
- 24 December 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7  (8) , 8756-8770
Overexpression of miR-199a-5p decreases esophageal cancer cell proliferation through repression of mitogen-activated protein kinase kinase kinase-11 (MAP3K11)
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Kimberly A. Byrnes1, 2, Pornima Phatak1, 2, Daniel Mansour1, 2, Lan Xiao1, 2, Tongtong Zou1, 2, Jaladanki N. Rao1, 2, Douglas J. Turner1, 2, Jian-Ying Wang1, 2, 3, James M. Donahue1, 2 1Department of Surgery, Cell Biology Group, University of Maryland School of Medicine, Baltimore, MD 21201, U.S.A 2Baltimore Veterans Affairs Medical Center, Baltimore, MD 21201, U.S.A 3Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, U.S.A Correspondence to: James M. Donahue, e-mail: jdonahue@smail.umaryland.edu Keywords: miR-199a-5p, MAP3K11, esophageal cancer, mRNA stability, proliferation Received: August 08, 2015 Accepted: November 16, 2015 Published: December 24, 2015 ABSTRACT Studies examining the oncogenic or tumor suppressive functions of dysregulated microRNAs (miRs) in cancer cells may also identify novel miR targets, which can themselves serve as therapeutic targets. Using array analysis, we have previously determined that miR-199a-5p was the most downregulated miR in two esophageal cancer cell lines compared to esophageal epithelial cells. MiR-199a-5p is predicted to bind mitogen-activated protein kinase kinase kinase 11 (MAP3K11) mRNA with high affinity. In this study, we observed that MAP3K11 is markedly overexpressed in esophageal cancer cell lines. Forced expression of miR-199a-5p in these cells leads to a decrease in the mRNA and protein levels of MAP3K11, due to decreased MAP3K11 mRNA stability. A direct binding interaction between miR-199a-5p and MAP3K11 mRNA is demonstrated using biotin pull-down assays and heterologous luciferase reporter constructs and confirmed by mutational analysis. Finally, forced expression of miR-199a-5p decreases proliferation of esophageal cancer cells by inducing G2/M arrest. This effect is mediated, in part, by decreased transcription of cyclin D1, due to reduced MAP3K11-mediated phosphorylation of c-Jun. These findings suggest that miR-199a-5p acts as a tumor suppressor in esophageal cancer cells and that its downregulation contributes to enhanced cellular proliferation by targeting MAP3K11.
- 24 December 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7  (8) , 8756-8770
Open AccessOverexpression of miR-199a-5p decreases esophageal cancer cell proliferation through repression of mitogen-activated protein kinase kinase kinase-11 (MAP3K11)
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Kimberly A. Byrnes1, 2, Pornima Phatak1, 2, Daniel Mansour1, 2, Lan Xiao1, 2, Tongtong Zou1, 2, Jaladanki N. Rao1, 2, Douglas J. Turner1, 2, Jian-Ying Wang1, 2, 3, James M. Donahue1, 2 1Department of Surgery, Cell Biology Group, University of Maryland School of Medicine, Baltimore, MD 21201, U.S.A 2Baltimore Veterans Affairs Medical Center, Baltimore, MD 21201, U.S.A 3Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, U.S.A Correspondence to: James M. Donahue, e-mail: jdonahue@smail.umaryland.edu Keywords: miR-199a-5p, MAP3K11, esophageal cancer, mRNA stability, proliferation Received: August 08, 2015 Accepted: November 16, 2015 Published: December 24, 2015 ABSTRACT Studies examining the oncogenic or tumor suppressive functions of dysregulated microRNAs (miRs) in cancer cells may also identify novel miR targets, which can themselves serve as therapeutic targets. Using array analysis, we have previously determined that miR-199a-5p was the most downregulated miR in two esophageal cancer cell lines compared to esophageal epithelial cells. MiR-199a-5p is predicted to bind mitogen-activated protein kinase kinase kinase 11 (MAP3K11) mRNA with high affinity. In this study, we observed that MAP3K11 is markedly overexpressed in esophageal cancer cell lines. Forced expression of miR-199a-5p in these cells leads to a decrease in the mRNA and protein levels of MAP3K11, due to decreased MAP3K11 mRNA stability. A direct binding interaction between miR-199a-5p and MAP3K11 mRNA is demonstrated using biotin pull-down assays and heterologous luciferase reporter constructs and confirmed by mutational analysis. Finally, forced expression of miR-199a-5p decreases proliferation of esophageal cancer cells by inducing G2/M arrest. This effect is mediated, in part, by decreased transcription of cyclin D1, due to reduced MAP3K11-mediated phosphorylation of c-Jun. These findings suggest that miR-199a-5p acts as a tumor suppressor in esophageal cancer cells and that its downregulation contributes to enhanced cellular proliferation by targeting MAP3K11.